1. Verbalize the rationale behind novel immunotherapies for cancer
  2. Articulate the clinical efficacy and potential toxicities of these therapies
  3. Describe the biology and ongoing clinical development of combination immunotherapies and mechanisms of resistance



Session date: 
01/13/2017 - 8:00am to 9:00am CST
NorthShore - Evanston
Evanston, IL 60201
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Thomas F. Gajewski, MD, PhD